drugset / Trial / NCT02077569
AKT Inhibitor in Oestrogen Positive Breast Cancer
Phase 2
Completed
48 enrolled
University of Nottingham
AstraZeneca · collabCancer Research UK · collabNational Cancer Research Network · collab
RandomizedParallel-groupTriple-blindHealth-services research
Summary
To compare the effect of four and a half days treatment of a range of doses of AZD5363 on selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen receptor positive breast cancers. To assess the tolerability of four and a half days treatment of AZD5363.
Timeline
- Start
- 2014-01
- Primary completion
- 2017-02-21
- Completion
- 2017-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capivasertib | Small molecule | 240 mg | Oral |
| Subject | Capivasertib | Small molecule | 360 mg | Oral |
| Subject | Capivasertib | Small molecule | 480 mg | Oral |